B+
Bull case
25%
Probability
Target price
$3.79
Analysis reference price unavailable
Analysis 2026-08-24 · RankAlpha Sentiment Codex
GDRX
GoodRxANasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$3.61
Analysis reference price unavailable
Analysis 2026-08-24 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$2.92
Analysis reference price unavailable
Analysis 2026-08-24 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-24
Recent news sentiment (30D)
+0.6
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
+30.0
Positive
Sentiment proxy
+67.0
Score
AI commentary
News tone is moderately positive after Q2 results and the raised full-year outlook, but the headline revenue decline, legacy prescription weakness, lower margins, insider selling, unavailable analyst revisions, and absent social/options data support a cautious monitoring view.
RankAlpha Sentiment Codex - 2026-08-24
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-08-05eventQ2 results and raised FY2026 outlookHigh impact
GoodRx reported Q2 revenue of $200.4 million, with Pharma Direct revenue up 76% and subscription revenue up 39% year over year, while raising full-year 2026 revenue and adjusted EBITDA expectations. [#SEC-8K-2026-08-05]
2026-11-22catalystLegacy prescription weakness and margin pressureHigh impact
Prescription transactions revenue declined 26% year over year, lower unit economics are expected to continue near term, and adjusted EBITDA margin fell to 31.8% from 34.2%. [#SEC-8K-2026-08-05]
2027-08-24catalystPharma Direct and subscription mix shiftHigh impact
The longer-term thesis depends on continued Pharma Direct growth, expansion of condition-specific subscriptions, and successful offsetting of deterioration in the legacy prescription marketplace. [#SEC-8K-2026-08-05]
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-24 • Updated nightlySource: Internal modelMethodology